Tilavonemab
Based on 1 Customer Validation
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.59%
- CAS No.: 2096513-89-0
- Masse moléculaire:145 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
Tau
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human Tau Protein (His Tag) can bind Tilavonemab. The EC50 for this effect is 2.182 ng/mL. -
Flow cytometric analysis of 1.5X106 SHSY5Y cells labeling Tilavonemab (HY-P99163, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.
Product Details
-
CAS No. 2096513-89-0
-
Accession P10636
-
Synonyms ABBV-8E12; C2N-8E12
-
Masse moléculaire 145 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG4 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG4 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureté
99.59%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Livraison
Shipping with dry ice.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Vaswani P A, et al. Immunotherapy in progressive supranuclear palsy. Curr Opin Neurol. 2020 Aug;33(4):527-533. [Content Brief]
[2]. Lopez-Cuina M, et al. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders[J]. Revue Neurologique, 2022, 178(5): 460-471. [Content Brief]
[3]. Neațu M, et al. Monoclonal antibody therapy in Alzheimer’s disease[J]. Pharmaceutics, 2023, 16(1): 60. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)